Search
Benserazide
go.drugbank.com/drugs/DB12783ApprovedInvestigationalWhen levodopa is used by itself as a therapy for treating Parkinson's disease, its ubiquitous metabolism into dopamine is responsible for a resultant increase in the levels of circulating dopamine in the blood and to various extracerebra...
Mixtures: LEVODOPA P BENS AL 100/25, LEVODOPA P BENS AL 100/25Larotrectinib
go.drugbank.com/drugs/DB14723ApprovedInvestigationalLarotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell gr...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesDexchlorpheniramine maleate
go.drugbank.com/drugs/DB09555ApprovedDexchlorpheniramine is the S-enantiomer of chlorpheniramine which is a 1st generation anti-histamine. Dexchlorpheniramine has more pharmacological activity than the R and so is more potent than the racemic mixture.
Mixtures: Corzall PECategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsBrasofensine
go.drugbank.com/drugs/DB04857ExperimentalIn November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230.
Trimethoprim
go.drugbank.com/drugs/DB00440ApprovedInvestigationalVet approvedTrimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it prevents the synthesis of bacterial ...
Mixtures: Nu-cotrimox Tab 400/80mg, Nu-cotrimox Sus 40/8mg/mlCategories: P-glycoprotein inducers, P-glycoprotein inhibitorsVoxilaprevir
go.drugbank.com/drugs/DB12026ApprovedInvestigationalVoxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV) … Prior to Vosevi, there were no approved retreatment options for patients who have previously received, and failed, a regimen containing an NS5A inhibitor for treatment of chronic HCV infection.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesNCX 701
go.drugbank.com/drugs/DB05409ExperimentalNitroparacetamol (NCX-701) is a newly synthesized nitric oxide-releasing derivative of paracetamol.
TL-895
go.drugbank.com/drugs/DB16471InvestigationalTL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates